{
    "Trade/Device Name(s)": [
        "ADVIA Centaur\u00ae anti-CCP IgG (aCCP) Assay",
        "ADVIA Centaur\u00ae anti-CCP IgG (aCCP) Quality Controls",
        "ADVIA Centaur\u00ae anti-CCP IgG (aCCP) Master Curve Materials",
        "ADVIA Centaur\u00ae anti-CCP IgG (aCCP) Quality Control",
        "ADVIA Centaur\u00ae anti-CCP IgG (aCCP) Master Curve Material (MCM)"
    ],
    "Submitter Information": "Axis-Shield Diagnostics Ltd",
    "510(k) Number": "K153551",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083868"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NHX",
        "JJX"
    ],
    "Summary Letter Date": "July 18, 2016",
    "Summary Letter Received Date": "July 19, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5775",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Rheumatoid Factor Immunological Test System",
        "Single (Specified) Analyte Control"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP)",
        "Anti-CCP IgG"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "Lithium heparin tube",
        "Serum Separator Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP system",
        "ADVIA Centaur systems"
    ],
    "Method(s)/Technology(ies)": [
        "Automated immunoassay",
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent detection",
        "Two-step assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Quality Control",
        "Master Curve Material"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur anti-CCP IgG assay and associated controls and master curve material for semi-quantitative detection of anti-CCP autoantibodies in serum/plasma to aid in diagnosing rheumatoid arthritis",
    "Indications for Use Summary": "For in vitro semi-quantitative determination of IgG class autoantibodies to cyclic citrullinated peptide (CCP) in human serum or plasma using the ADVIA Centaur XP system; used as an aid in the diagnosis of rheumatoid arthritis in conjunction with clinical assessment; quality control and master curve material are for monitoring assay performance and calibration.",
    "fda_folder": "Immunology"
}